• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
FIGURE 17. Withdrawals and crossovers in ACCENT I.

FIGURE 17Withdrawals and crossovers in ACCENT I2,3

* (CiC information has been removed). R, randomisation. Note: Dropouts (DOs) and week 14 or later crossovers (XOs) allowed ‘as required’.

From: 3, Assessment of clinical effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.